Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
This was the stock's third consecutive day of gains.
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Zacks.com on MSN2d
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...
Levi & Korsinsky Reminds Vertex Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VRTX
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Zacks Research Has Positive Estimate for VRTX Q3 Earnings
Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...
Yahoo Finance12d
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (NASDAQ ... Image source: Getty Images. First, let's consider the Vertex story so far. The company has built a CF empire, offering several treatments known as CFTR modulators.